GlassScriptPhysician profile
Sumayya Naz
NPI 1699327346
$1,498.14
in general payments reported to CMS, 2019-2025
25 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.40 · 2022: $257 · 2023: $585 · 2024: $502 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $251.84 | 2022-2024 | Briviact, Fintepla |
| Sk Life Science, INC. | $248.94 | 2021-2025 | |
| Celgene Corporation | $175.54 | 2023-2024 | Zeposia |
| Neurelis, INC. | $145.83 | 2023-2024 | Valtoco |
| Argenx US, INC. | $99.07 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $76.01 | 2023-2024 | |
| Pfizer INC. | $48.47 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.18 | 2023-2024 | Hyqvia |
| Lundbeck LLC | $46.51 | 2023-2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $34.95 | 2022 | |
| Biogen, INC. | $33.28 | 2021-2024 | Skyclarys |
| Acadia Pharmaceuticals INC | $32.26 | 2023-2024 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $29.55 | 2022-2023 | Onpattro |
| Mdd US Operations, LLC | $28.01 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.10 | 2022-2023 | Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $21.33 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $20.67 | 2024 | |
| Lilly USA, LLC | $19.72 | 2024 | Reyvow, Emgality |
| Sumitomo Pharma America, INC. | $18.53 | 2023 | Aptiom |
| Eisai INC. | $18.27 | 2023 | |
| Emd Serono, INC. | $18.21 | 2025 | |
| Biocodex, INC. | $15.33 | 2025 | |
| Csl Behring | $15.18 | 2024 | Hizentra |
| Novartis Pharmaceuticals Corporation | $14.86 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumayya Naz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.